Lusutrombopag manufacturers, specifications and sales channels

Lusutrombopag is an oral thrombopoietic drug that is mainly used in patients with chronic liver disease to increase platelet levels and reduce the risk of bleeding before planned invasive procedures. Its mechanism of action is to selectively activate thrombopoietin receptors, promote bone marrow megakaryocyte proliferation and platelet production, thereby improving thrombocytopenia.

In the domestic market, Rutrombopag tablets have been officially launched, and the manufacturers are major domestic pharmaceutical companies. Drug specifications are usually fixed dosage per tablet, making it easy to adjust the medication cycle according to body weight or doctor's prescription. Drug sales cover the pharmacies of all major tertiary hospitals and some second-level hospitals across the country, and drugs are circulated through formal channels to ensure that patients can obtain reliable drug sources for clinical use.

In terms of price, a box of Rutrombopag tablets in China sells for between three and four thousand yuan, and has been included in the medical insurance reimbursement system. The specific reimbursement ratio and patient out-of-pocket amount need to be determined based on local medical insurance policies and hospital settlement regulations, so that the patient's financial burden is relatively controllable. For patients with chronic liver disease that require multiple procedures or long-term management, medical insurance coverage significantly reduces treatment costs.

Rutrombopag tablets are also available as generic drugs in overseas markets. For example, a box of tablets produced in Laos sells for about more than 1,000 yuan, which is cheaper than the domestic original drug. The existence of overseas generic drugs provides international patients with more choices, but attention must be paid to the formality of drug sources and quality standards. In clinical application, treatment plans should be reasonably arranged based on the patient's economic conditions, drug safety, and access channels.

Keyword tags: Rutrombopag, thrombocytopenia, manufacturer, medical insurance, price

Reference materials:https://pubmed.ncbi.nlm.nih.gov/26666417/